In the press
Recent interview with Mergermarket, Acuris
As Redbiotec prepares for a Series A financing round to take the most advanced asset – immunotherapy for HSV2-associated genital herpes – into Phase I/IIa clinical trial, CEO Christian Schaub recently spoke with Mergermarket about company plans and visions.
Analysis of Redbiotec by In Vivo (Informa Pharma Intelligence)
Redbiotec Pivots Toward HSV-2 Therapies And Therapeutic Bacteria
Redbiotec has reached a new inflection point as it progresses two key programs in herpes and cancer. The company’s CEO and CSO explain how it hopes to use bacteria as a delivery system for genes or proteins to treat cancer.
Article about Redbiotec in “Handelszeitung”. Read here.
Article “KMU Special”
Another nice article about Redbiotec in “KMU Special”. Read article.
Article about Redbiotec in “Bilanz”. Read article.